Drugs News and Research

RSS

DEA, Harvard Drug Group announce agreement to modify suspension

Today, the Drug Enforcement Administration and U.S. Attorney's Office, and Harvard Drug Group announced their agreement to immediately modify the suspension, upon certain conditions, of Harvard's registration to distribute schedule III through V controlled substances out of its Livonia Distribution Center, and a mutual commitment to commence discussions, towards resolution of the issues raised in the DEA's suspension order. The suspension remains as to schedule II controlled substances.

19 Jun 2010

Preclinical study shows treatment with DAS181 inhibits infection with multiple HPIV strains

NexBio, Inc. announced today the publication of a "Major Article" in the Journal of Infectious Diseases of a preclinical study showing that treatment with DAS181 (Fludase) inhibits infection with multiple human parainfluenza virus strains. DAS181 is a broad spectrum host-targeted investigational drug candidate for treatment and prevention of Influenza-Like Illness.

19 Jun 2010

Health Robotics announces new Canadian marketing contracts for i.v.STATION, i.v.SOFT

Health Robotics announced that its joint-venture Health Robotics Canada Inc. (HRCI), a leading Canadian Pharmaceutical Company, and a well-established Quebec-based Medical Device Technology company have all recently signed marketing agreements in order to expand into Canada the market presence of i.v.STATION and i.v.SOFT, revolutionary technologies that provide automated sterile compounding of intravenous medications and parenteral nutrition to hospitals.

19 Jun 2010

Drug-resistant malaria spreading beyond Western Cambodia, U.S. malaria coordinator says

Resistance to artemisinin-based malaria medications seems to be spreading beyond western Cambodia, where it was first detected, U.S. global malaria coordinator Timothy Ziemer said during a visit to the region this week for a conference, Agence France-Presse reports.

19 Jun 2010

Montana Governor visits Cannabis Science's latest acquisition

Cannabis Science, Inc., a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased to report that Montana Governor Brian Schweitzer visited its latest acquisition, Montana Pain Management in Missoula, yesterday. Governor Schweitzer observed, "You are doing it right."

19 Jun 2010

Research roundup: Medical homes working in poor areas, designing insurance exchanges, health law's effects

Moving Forward On Health Reform - This edition explores the issues relating to the implementation of the Patient Protection and Affordable Care Act of 2010, including the impact of the law on health insurance as well as state and federal governments, large employers and public opinion and opportunities for small physician practices to pool resources in order support medical homes, among others (June 2010).

19 Jun 2010

HBSS reaches $103M settlement with Astra Zeneca

Hagens Berman Sobol Shapiro (HBSS) today announced it has reached a proposed $103 million settlement with Astra Zeneca (AZ) on behalf of consumers and third party purchasers. The class-action lawsuit claimed Astra Zeneca inflated the Average Wholesale Price (AWP), which is used as a benchmark for almost all prescription drug sales in the United States.

19 Jun 2010

Tongjitang first-quarter net revenue up 25.6% to $16.6 million

Tongjitang Chinese Medicines Company, a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced its financial results for the quarter ended March 31, 2010.

19 Jun 2010

Lawmakers want crackdown on drug agreements that keep generics out

Democrats are looking at proposals to crack down on licensing agreements between drug companies that keep generic drugs out of the market, Politico reports. In the agreements, pharmaceutical companies pay generic manufacturers to "delay introduction of generic drugs, which are often cheaper than brand-name drugs.

18 Jun 2010

Advisory panel recommends FDA approve new "morning after" pill

The New York Times: A Food and Drug Administration advisory panel Thursday recommended that the agency approve "a medicine that could help prevent pregnancy if taken as late as five days after unprotected sex. The pill, called ella, sprang from government labs and appears to be more effective than Plan B, a morning-after pill now available over the counter to women 18 and older that gradually loses efficacy after intercourse and can be taken at latest three days after sex.

18 Jun 2010

Gladstone Institute researcher to receive Kyoto Prize in Advanced Technology

The non-profit Inamori Foundation (President: Dr. Kazuo Inamori) today announced that Dr. Shinya Yamanaka will receive its 26th annual Kyoto Prize in Advanced Technology, which for 2010 focuses on the fields of Biotechnology and Medical Technology. Dr. Yamanaka, 47, will receive the award for his pioneering work in developing a technology to generate pluripotent stem cells that does not require the use of human embryos.

18 Jun 2010

Additional results from BLISS-52 Phase 3 trial of BENLYSTA for SLE to be presented at EULAR 2010

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced the presentation of additional results from BLISS-52, one of two pivotal Phase 3 trials of BENLYSTA (belimumab) in seropositive patients with systemic lupus erythematosus. The additional data will be presented in Rome at the 2010 Congress of the European League against Rheumatism on Saturday, June 19.

18 Jun 2010

Expression of BCRP in RA patients may indicate higher disease activity, predict resistance to DMARDs

The expression of a transporter protein called the Breast Cancer Resistance Protein in rheumatoid arthritis patients may indicate higher disease activity and could be a barrier to the effectiveness of disease-modifying antirheumatic drugs, according to the results of a study presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy.

18 Jun 2010

Nationwide campaign encourages teens to resist drug use, stay above negative influences

Milwaukee teens are part of the White House Office of National Drug Control Policy's new, nationwide campaign encouraging teens to engage in a conversation about the positive and negative pressures that influence their decisions. The Influence Project is part of a new initiative of the anti-drug teen brand, Above the Influence, which emphasizes what teens do to resist drug use and stay "above" negative influences.

18 Jun 2010

Completion of drug analysis by PBS-Bio enables PharmaGap advance development of novel anti-cancer drug

Predictive Biomarker Sciences Inc. (PBS-Bio) has completed its first drug analysis, enabling Canadian biotech company PharmaGap Inc. to significantly advance a potentially significant anti-cancer medication.

18 Jun 2010

Trial eases concerns over effects of gamma secretase inhibitors for Alzheimer's disease treatment

The first trial of a new model for testing Alzheimer's treatments has reassured researchers that a promising class of drugs does not exacerbate the disease if treatment is interrupted.

18 Jun 2010

New multimillion dollar BSL-3 laboratory complex at Nigerian National TB and Leprosy Training Center

This week, the U.S. Centers for Disease Control (CDC) Director, Dr. Tom Frieden, visited the Nigerian National TB and Leprosy Training Center (NTBLTC) to tour a multimillion dollar laboratory complex established by the Institute of Human Virology (IHV) of the University of Maryland School of Medicine in Baltimore, Maryland, and the Institute of Human Virology-Nigeria. This U.S.-Nigeria partnership was established in 2004 through funding from the CDC and the President's Emergency Plan For AIDS Relief (PEPFAR).

18 Jun 2010

Researchers identify how obese people become salt sensitive, hypertensive

One way obese people become salt sensitive and hypertensive has been identified by Medical College of Georgia researchers.

18 Jun 2010

Consumption of tea increases risk of Rheumatoid Arthritis in women

Women who drink tea have an increased risk of developing Rheumatoid Arthritis (RA) compared with those who drink none.

18 Jun 2010

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its FDA-approved diabetes drugs, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection, and its investigational diabetes drug candidate BYDUREON (exenatide extended-release for injectable suspension) at the American Diabetes Association's 70th Annual Scientific Sessions being held in Orlando, FL from June 25 to June 29.

18 Jun 2010

Drugs News and Research

DEA, Harvard Drug Group announce agreement to modify suspension

Preclinical study shows treatment with DAS181 inhibits infection with multiple HPIV strains

Health Robotics announces new Canadian marketing contracts for i.v.STATION, i.v.SOFT

Drug-resistant malaria spreading beyond Western Cambodia, U.S. malaria coordinator says

Montana Governor visits Cannabis Science's latest acquisition

Research roundup: Medical homes working in poor areas, designing insurance exchanges, health law's effects

HBSS reaches $103M settlement with Astra Zeneca

Tongjitang first-quarter net revenue up 25.6% to $16.6 million

Lawmakers want crackdown on drug agreements that keep generics out

Advisory panel recommends FDA approve new "morning after" pill

Gladstone Institute researcher to receive Kyoto Prize in Advanced Technology

Additional results from BLISS-52 Phase 3 trial of BENLYSTA for SLE to be presented at EULAR 2010

Expression of BCRP in RA patients may indicate higher disease activity, predict resistance to DMARDs

Nationwide campaign encourages teens to resist drug use, stay above negative influences

Completion of drug analysis by PBS-Bio enables PharmaGap advance development of novel anti-cancer drug

Trial eases concerns over effects of gamma secretase inhibitors for Alzheimer's disease treatment

New multimillion dollar BSL-3 laboratory complex at Nigerian National TB and Leprosy Training Center

Researchers identify how obese people become salt sensitive, hypertensive

Consumption of tea increases risk of Rheumatoid Arthritis in women

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

Drug Discovery - Second Edition eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News